Patents matching “antibody”

US 11666658

Rifamycin analogs and antibody-drug conjugates thereof

REGENERON PHARMACEUTICALS, INC. · Granted Jun 6, 2023 · Expires Jun 1, 2043

US 11666594

Antibody-drug conjugates comprising a cyclic dinucleotide

Takeda Pharmaceutical Company Limited · Granted Jun 6, 2023 · Expires Jun 1, 2043

US 11667900

Compositions and methods for enhancing macrophage-mediated antibody guided cancer cell or tumor eradication

The Regents of the University of California · Granted Jun 6, 2023 · Expires Jun 1, 2043

US 11648318

Anti-transferrin receptor (TFR) antibody and uses thereof

Dyne Therapeutics, Inc. · Granted May 16, 2023 · Expires May 11, 2043

US 11642390

Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibody

REGENERON PHARMACEUTICALS, INC. · Granted May 9, 2023 · Expires May 4, 2043

US 11638760

Pyrrolobenzodiazepine antibody conjugates

Mersana Therapeutics, Inc. · Granted May 2, 2023 · Expires Apr 27, 2043

US 11633501

Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Apr 25, 2023 · Expires Apr 20, 2043

US 11629122

Linkers for antibody drug conjugates

The Board of Regents of the University of Texas System · Granted Apr 18, 2023 · Expires Apr 13, 2043

US 11608381

Methods of treatment using a leptin receptor agonist antibody

REGENERON PHARMACEUTICALS, INC. · Granted Mar 21, 2023 · Expires Mar 16, 2043

US 11603407

Stable antibody formulation

REGENERON PHARMACEUTICALS, INC. · Granted Mar 14, 2023 · Expires Mar 9, 2043

US 11596696

Combination therapy with an anti-CD25 antibody-drug conjugate

ADC THERAPEUTICS SA · Granted Mar 7, 2023 · Expires Mar 2, 2043

US 11597773

CD6 antibody for treatment of T-cell mediated diseases or disorders

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Mar 7, 2023 · Expires Mar 2, 2043

US 11597774

Antibody variable domains and antibody constructs

The Board of Regents of the University of Texas System · Granted Mar 7, 2023 · Expires Mar 2, 2043

US 11596688

Predicting outcome of treatment with an anti-α4β7 integrin antibody

Takeda Pharmaceutical Company Limited · Granted Mar 7, 2023 · Expires Mar 2, 2043

US 11576863

Formulation of an antibody and use thereof

Takeda Pharmaceutical Company Limited · Granted Feb 14, 2023 · Expires Feb 9, 2043

US 11572408

Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent

VACCINEX, INC. · Granted Feb 7, 2023 · Expires Feb 2, 2043

US 11566076

Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers

Five Prime Therapeutics, Inc. · Granted Jan 31, 2023 · Expires Jan 26, 2043

US 11559583

Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. · Granted Jan 24, 2023 · Expires Jan 19, 2043

US 11555064

Treating headache comprising administering an antibody to calcitonin gene-related peptide

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jan 17, 2023 · Expires Jan 12, 2043

US 11548953

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof

The Regents of the University of California · Granted Jan 10, 2023 · Expires Jan 5, 2043

US 11548940

Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Rani Therapeutics, LLC · Granted Jan 10, 2023 · Expires Jan 5, 2043

US 11547761

Antibody adjuvant conjugates

Bolt Biotherapeutics, Inc. · Granted Jan 10, 2023 · Expires Jan 5, 2043

US 11542338

CD38 modulating antibody

BLACK BELT THERAPEUTICS LIMITED · Granted Jan 3, 2023 · Expires Dec 29, 2042

US 11534495

Tissue factor-targeted antibody-drug conjugate

SHANGHAI MIRACOGEN INC. · Granted Dec 27, 2022 · Expires Dec 22, 2042